Blue Diamond Ventures Inc (BLDV)

[JPS02]

FDA Panel Recommends Marijuana Product To Treat Epilepsy | NBC Nightly News

NBC News | Published on Apr 19, 2018

Epidiolex, which has been proven to treat some severe forms of epilepsy, does not contain THC, the compound that gets marijuana users high.

Source: https://www.youtube.com/watch?v=_ZksFb2kwY0

DEA permits GW Pharma to sell cannabis derived drug, CEO says there is an 'acute need' for the medic

CNBC Television | Published on Sep 27, 2018

CNBC's Meg Tirrell reports that the Drug Enforcement Administration recently approved GW Pharma to sell a new cannabis derived drug. The company's CEO, Justin Gover, said that people suffering from epilepsy have been waiting for the medication to be approved.

Source: https://www.youtube.com/watch?v=9HJQ5Pwzw6U

Dr. Laura Lubbers Discusses Epidiolex on MichaeLA

CURE - Citizens United for Research In Epilepsy | Published on Jul 5, 2018

CURE's Chief Scientific Office Dr. Laura Lubbers speaks on MichaeLA about Epidiolex and what its FDA approval means for those with epilepsy.

Source: https://www.youtube.com/watch?v=ocs-r_VOJXc

- Numbmonk, I think you may be onto something very significant with your post that has key thoughts which are worth reflecting on after viewing the 3 YT clips above. GW Pharmaceuticals' Epidiolex was the first CBD oil to receive FDA approval and DEA rescheduling. In the second YT clip, notice how the GW CEO says that if you apply the rigours of science and law to cannabis research, the FDA and DEA will act and respond to the needs of patients.

- The important point is the pharma grade aspect of producing the CBD oil which I think may have been important to the recent conditional approval of the application in Virginia for BLDV's client; this shows the potential demand for this approach. It will be interesting to see how Cann10's Cannareet enters the North American market. Notice how the licensing of Cannareet is regularly mentioned in previous BLDV PRs - one of which was related to the Virginia application, see highlights posts below:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144193410

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143333258

In the June 2018 interview, the BLDV CEO explained BLDV and Cann10's science approach to medical cannabis:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=142433639&txt2find=pharma

Go BLDV!